Neuroleptic malignant syndrome: a rare long lasting case report.
DOI:
https://doi.org/10.20344/amp.732Abstract
Neuroleptic malignant syndrome (NMS) is a neurological emergency related to neuroleptics medication. Diagnosis is clinical. Authors present the case of a 32-year-old Caucasian man with a history of moderated oligophreny treated with stable doses of psychotropic and neuroleptic drugs. Because of aggressivity outbreaks, he was administered high doses of intramuscular haloperidol decanoate for a period of ten days. One month later he had evolved with mental deterioration, mutism, generalized rigidity, fever, tachycardia, hypotension and diaphoresis. Neuroleptic malignant syndrome was diagnosed. Supporting treatment was provided and intercurrences treated. Neuroleptic malignant syndrome is a fatal disease in 10 to 20% of patients; otherwise it resolves in about two weeks. In rare cases, like this one the authors report, it has a prolonged evolution of months.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
